

Patr cio Soares da Silva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3566836/publications.pdf>

Version: 2024-02-01

388
papers

11,484
citations

30070

54
h-index

53230

85
g-index

392
all docs

392
docs citations

392
times ranked

8254
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacokinetic and safety profile of <i>trans</i> -resveratrol in a rising multiple-dose study in healthy volunteers. <i>Molecular Nutrition and Food Research</i> , 2009, 53, S7-15.	3.3	363
2	Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. <i>Neurochemical Research</i> , 2002, 27, 121-130.	3.3	250
3	Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: A randomized, double-blind, placebo-controlled, parallel-group phase III study. <i>Epilepsia</i> , 2009, 50, 454-463.	5.1	241
4	Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. <i>Lancet Neurology</i> , The, 2016, 15, 154-165.	10.2	219
5	Anticonvulsant and Sodium Channel-Blocking Properties of Novel 10,11-Dihydro-5H-dibenz[b,f]azepine-5-carboxamide Derivatives. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 2582-2587.	6.4	189
6	Dopamine 5 receptor mediates Ang II type 1 receptor degradation via a ubiquitin-proteasome pathway in mice and human cells. <i>Journal of Clinical Investigation</i> , 2008, 118, 2986-2986.	8.2	181
7	Eslicarbazepine acetate (BIA 2-093). <i>Neurotherapeutics</i> , 2007, 4, 88-96.	4.4	180
8	Impaired synthesis or cellular storage of norepinephrine, dopamine, and 5-hydroxytryptamine in human inflammatory bowel disease. <i>Digestive Diseases and Sciences</i> , 2002, 47, 216-224.	2.3	175
9	Catechol-O-methyltransferase and Its Inhibitors in Parkinson's Disease. <i>CNS Neuroscience & Therapeutics</i> , 2007, 13, 352-379.	4.0	166
10	Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. <i>Epilepsy Research</i> , 2010, 89, 278-285.	1.6	166
11	Discovery of a Long-Acting, Peripherally Selective Inhibitor of Catechol-O-methyltransferase. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 3396-3411.	6.4	156
12	Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. <i>Acta Neurologica Scandinavica</i> , 2009, 120, 281-287.	2.1	155
13	Pharmacokinetics and drug interactions of eslicarbazepine acetate. <i>Epilepsia</i> , 2012, 53, 935-946.	5.1	151
14	Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations. <i>JAMA Neurology</i> , 2017, 74, 197.	9.0	146
15	Mice Lacking D ₅ Dopamine Receptors Have Increased Sympathetic Tone and Are Hypertensive. <i>Journal of Neuroscience</i> , 2002, 22, 10801-10810.	3.6	141
16	Eslicarbazepine Acetate: A Double-blind, Add-on, Placebo-controlled Exploratory Trial in Adult Patients with Partial-onset Seizures. <i>Epilepsia</i> , 2007, 48, 497-504.	5.1	119
17	Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: A comparison with carbamazepine, oxcarbazepine and lacosamide. <i>Neuropharmacology</i> , 2015, 89, 122-135.	4.1	111
18	Decrease of adenosine A ₁ receptor density and of adenosine neuromodulation in the hippocampus of kindled rats. <i>European Journal of Neuroscience</i> , 2003, 18, 820-828.	2.6	108

#	ARTICLE	IF	CITATIONS
19	Oxidative and non-oxidative mechanisms of neuronal cell death and apoptosis by L-3,4-dihydroxyphenylalanine (L-DOPA) and dopamine. <i>British Journal of Pharmacology</i> , 2002, 137, 1305-1313.	5.4	105
20	Single-Dose and Steady-State Pharmacokinetics of Eslicarbazepine Acetate (BIA 2-093) in Healthy Elderly and Young Subjects. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 1062-1066.	2.0	104
21	Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 267-273.	1.9	102
22	Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial. <i>Epilepsia</i> , 2015, 56, 244-253.	5.1	101
23	Pharmacokinetics of <i>Trans</i> -Resveratrol Following Repeated Administration in Healthy Elderly and Young Subjects. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 1477-1482.	2.0	98
24	Interaction of the Novel Anticonvulsant, BIA 2-093, with Voltage-Gated Sodium Channels: Comparison with Carbamazepine. <i>Epilepsia</i> , 2001, 42, 600-608.	5.1	95
25	Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(�)-10,11-dihydro-10-hydroxy carbamazepine. <i>Epilepsy Research</i> , 2001, 44, 197-206.	1.6	93
26	Long-term efficacy and safety of eslicarbazepine acetate: Results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy. <i>Epilepsia</i> , 2010, 51, 1963-1969.	5.1	92
27	Dopamine and G protein-coupled receptor kinase 4 in the kidney: Role in blood pressure regulation. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2010, 1802, 1259-1267.	3.8	90
28	Medicinal Chemistry of Catechol <i>O</i> -Methyltransferase (COMT) Inhibitors and Their Therapeutic Utility. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 8692-8717.	6.4	88
29	Long-term Effect of Convulsive Behavior on the Density of Adenosine A ₁ and A _{2A} Receptors in the Rat Cerebral Cortex. <i>Epilepsia</i> , 2005, 46, 159-165.	5.1	87
30	Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Integrated analysis of pooled data from double-blind phase III clinical studies. <i>Epilepsia</i> , 2013, 54, 98-107.	5.1	85
31	L-DOPA transport properties in an immortalised cell line of rat capillary cerebral endothelial cells, RBE 4. <i>Brain Research</i> , 1999, 829, 143-150.	2.2	82
32	Kinetics and Crystal Structure of Catechol-O-Methyltransferase Complex with Co-Substrate and a Novel Inhibitor with Potential Therapeutic Application. <i>Molecular Pharmacology</i> , 2002, 62, 795-805.	2.3	81
33	Carbamazepine inhibits L-type Ca ²⁺ channels in cultured rat hippocampal neurons stimulated with glutamate receptor agonists. <i>Neuropharmacology</i> , 1999, 38, 1349-1359.	4.1	79
34	Pharmacokinetics, Pharmacodynamics and Tolerability of Opicapone, a Novel Catechol-O-Methyltransferase Inhibitor, in Healthy Subjects. <i>Clinical Pharmacokinetics</i> , 2013, 52, 139-151.	3.5	79
35	Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 763-775.	2.4	76
36	Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: Results of a 1-year open-label extension study. <i>Epilepsy Research</i> , 2013, 103, 262-269.	1.6	74

#	ARTICLE	IF	CITATIONS
37	Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug. <i>Brain</i> , 2015, 138, 371-387.	7.6	72
38	Dopamine 5 receptor mediates Ang II type 1 receptor degradation via a ubiquitin-proteasome pathway in mice and human cells. <i>Journal of Clinical Investigation</i> , 2008, 118, 2180-9.	8.2	72
39	Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized, parallel-group, multicenter study. <i>Epilepsia</i> , 2018, 59, 479-491.	5.1	69
40	Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. <i>Epilepsy Research</i> , 2011, 96, 132-139.	1.6	66
41	Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action. <i>Pharmacology Research and Perspectives</i> , 2015, 3, e00124.	2.4	66
42	The effect of dietary sodium restriction on neurohumoral activity and renal dopaminergic response in patients with heart failure. <i>European Journal of Heart Failure</i> , 2004, 6, 593-599.	7.1	65
43	Why healthy subjects volunteer for phase I studies and how they perceive their participation?. <i>European Journal of Clinical Pharmacology</i> , 2007, 63, 1085-1094.	1.9	65
44	Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers. <i>Epilepsia</i> , 2013, 54, 108-116.	5.1	65
45	Aging, High Salt Intake, and Renal Dopaminergic Activity in Fischer 344 Rats. <i>Hypertension</i> , 1999, 34, 666-672.	2.7	63
46	Angiotensin-II Type 1 Receptor-Mediated Hypertension in D 4 Dopamine Receptor-Deficient Mice. <i>Hypertension</i> , 2006, 47, 288-295.	2.7	62
47	Pharmacokinetics, Efficacy, and Tolerability of Eslicarbazepine Acetate in Children and Adolescents With Epilepsy. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 966-977.	2.0	62
48	Effects of tolcapone upon soluble and membrane-bound brain and liver catechol-O-methyltransferase. <i>Brain Research</i> , 1999, 821, 69-78.	2.2	60
49	A kinetic study of the rate of formation of dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in the brain of the rat: Implications for the origin of dopac. <i>Neuropharmacology</i> , 1990, 29, 869-874.	4.1	59
50	Synthesis of 1-(3,4-Dihydroxy-5-nitrophenyl)-2-phenyl-ethanone and Derivatives as Potent and Long-Acting Peripheral Inhibitors of Catechol-O-methyltransferase. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 685-695.	6.4	59
51	Synthesis and Biological Evaluation of Novel, Peripherally Selective Chromanyl Imidazolethione-Based Inhibitors of Dopamine β -Hydroxylase. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 1191-1197.	6.4	59
52	Aging increases Oxidative Stress and Renal Expression of Oxidant and Antioxidant Enzymes that Are Associated with an Increased Trend in Systolic Blood Pressure. <i>Oxidative Medicine and Cellular Longevity</i> , 2009, 2, 138-145.	4.0	59
53	Pharmacokinetics, Drug Interactions and Exposure-Response Relationship of Eslicarbazepine Acetate in Adult Patients with Partial-Onset Seizures. <i>CNS Drugs</i> , 2012, 26, 79-91.	5.9	58
54	Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 1059-1071.	1.9	58

#	ARTICLE	IF	CITATIONS
55	Safety, Tolerability, and Pharmacokinetic Profile of BIA 2-093, a Novel Putative Antiepileptic, in a Rising Multiple-Dose Study in Young Healthy Humans. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 906-918.	2.0	57
56	Development and validation of an HPLC-UV method for the simultaneous quantification of carbamazepine, oxcarbazepine, eslicarbazepine acetate and their main metabolites in human plasma. <i>Analytical and Bioanalytical Chemistry</i> , 2010, 397, 1605-1615.	3.7	56
57	Role of cAMP-PKA-PLC signaling cascade on dopamine-induced PKC-mediated inhibition of renal Na ⁺ -K ⁺ -ATPase activity. <i>American Journal of Physiology - Renal Physiology</i> , 2002, 282, F1084-F1096.	2.7	54
58	Defective D1-like receptor-mediated inhibition of the Cl ⁻ /HCO ₃ ⁻ exchanger in immortalized SHR proximal tubular epithelial cells. <i>American Journal of Physiology - Renal Physiology</i> , 2004, 286, F1120-F1126.	2.7	54
59	Neurotoxicity Induced by Antiepileptic Drugs in Cultured Hippocampal Neurons: A Comparative Study between Carbamazepine, Oxcarbazepine, and Two New Putative Antiepileptic Drugs, BIA 2-024 and BIA 2-093. <i>Epilepsia</i> , 2004, 45, 1498-1505.	5.1	53
60	Endogenous dopamine modulates jejunal sodium absorption during high-salt diet in young but not in adult rats. <i>Gastroenterology</i> , 1994, 107, 675-679.	1.3	52
61	Computation of the binding affinities of catechol-O-methyltransferase inhibitors: Multisubstrate relative free energy calculations. <i>Journal of Computational Chemistry</i> , 2012, 33, 970-986.	3.3	51
62	Expression of LAT1 and LAT2 amino acid transporters in human and rat intestinal epithelial cells. <i>Amino Acids</i> , 2005, 29, 229-233.	2.7	50
63	Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel blocker. <i>Biopharmaceutics and Drug Disposition</i> , 2007, 28, 249-256.	1.9	50
64	The novel anticonvulsant BIA 2-093 inhibits transmitter release during opening of voltage-gated sodium channels: a comparison with carbamazepine and oxcarbazepine. <i>Neurochemistry International</i> , 2002, 40, 435-440.	3.8	49
65	Effect of Food on the Pharmacokinetic Profile of Eslicarbazepine Acetate (BIA 2-093). <i>Drugs in R and D</i> , 2005, 6, 201-206.	2.2	48
66	Comparative Study of ortho- and meta-Nitrated Inhibitors of Catechol-O-methyltransferase: Interactions with the Active Site and Regioselectivity of O-Methylation. <i>Molecular Pharmacology</i> , 2006, 70, 143-153.	2.3	48
67	Neurotoxic/neuroprotective profile of carbamazepine, oxcarbazepine and two new putative antiepileptic drugs, BIA 2-093 and BIA 2-024. <i>European Journal of Pharmacology</i> , 2000, 406, 191-201.	3.5	45
68	Inhibition of glutamate release by BIA 2-093 and BIA 2-024, two novel derivatives of carbamazepine, due to blockade of sodium but not calcium channels. Abbreviations: AED, antiepileptic drug; CBZ, carbamazepine; OXC, oxcarbazepine; and 4-AP, 4-aminopyridine. <i>Biochemical Pharmacology</i> , 2001, 61, 1271-1275.	4.4	45
69	Evaluation of the permeability and P-glycoprotein efflux of carbamazepine and several derivatives across mouse small intestine by the Ussing chamber technique. <i>Epilepsia</i> , 2012, 53, 529-538.	5.1	45
70	Decreased availability of intestinal dopamine in transmural colitis may relate to inhibitory effects of interferon-gamma upon L-DOPA uptake. <i>Acta Physiologica Scandinavica</i> , 2004, 180, 379-386.	2.2	43
71	New Insights into the Regulation of Na ⁺ ,K ⁺ -ATPase by Ouabain. <i>International Review of Cell and Molecular Biology</i> , 2012, 294, 99-132.	3.2	43
72	A comparison between the pattern of dopamine and noradrenaline release from sympathetic neurones of the dog mesenteric artery. <i>British Journal of Pharmacology</i> , 1987, 90, 91-98.	5.4	42

#	ARTICLE	IF	CITATIONS
73	Over-expression of renal LAT1 and LAT2 and enhanced L-DOPA uptake in SHR immortalized renal proximal tubular cells. <i>Kidney International</i> , 2004, 66, 216-226.	5.2	42
74	Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects. <i>Acta Neurologica Scandinavica</i> , 2010, 121, 257-264.	2.1	41
75	A new PAMPA model using an in-house brain lipid extract for screening the blood-brain barrier permeability of drug candidates. <i>International Journal of Pharmaceutics</i> , 2016, 501, 102-111.	5.2	41
76	Evidence for a non-precursor dopamine pool in noradrenergic neurones of the dog mesenteric artery. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1986, 333, 219-223.	3.0	40
77	Interaction between L-DOPA and 3-O-methyl-L-DOPA for transport in immortalised rat capillary cerebral endothelial cells. <i>Neuropharmacology</i> , 1999, 38, 1371-1380.	4.1	40
78	Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease. <i>Neurology</i> , 2018, 90, e1849-e1857.	1.1	40
79	Molecular Modeling and Metabolic Studies of The Interaction of Catechol-O-Methyltransferase and a New Nitrocatechol Inhibitor. <i>Drug Metabolism and Disposition</i> , 2003, 31, 250-258.	3.3	39
80	Oxidative stress and the genomic regulation of aldosterone-stimulated NHE1 activity in SHR renal proximal tubular cells. <i>Molecular and Cellular Biochemistry</i> , 2008, 310, 191-201.	3.1	39
81	Effect of eslicarbazepine acetate on the pharmacokinetics of a combined ethinylestradiol/levonorgestrel oral contraceptive in healthy women. <i>Epilepsy Research</i> , 2013, 105, 368-376.	1.6	39
82	Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers. <i>Epilepsia</i> , 2013, 54, 1453-1461.	5.1	38
83	Dopamine D ₃ receptor-mediated inhibition of Na ⁺ /H ⁺ exchanger activity in normotensive and spontaneously hypertensive rat proximal tubular epithelial cells. <i>British Journal of Pharmacology</i> , 2004, 142, 1343-1353.	5.4	37
84	Synthesis, Biological Evaluation, and Molecular Modeling Studies of a Novel, Peripherally Selective Inhibitor of Catechol-O-methyltransferase. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 6207-6217.	6.4	37
85	Dopamine D2 Receptor Polymorphisms in Inflammatory Bowel Disease and the Refractory Response to Treatment. <i>Digestive Diseases and Sciences</i> , 2006, 51, 2039-2044.	2.3	37
86	Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers. <i>Epilepsy and Behavior</i> , 2010, 18, 366-373.	1.7	37
87	Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor. <i>Neuropharmacology</i> , 2014, 77, 334-341.	4.1	37
88	Deficiency of renal dopaminergic-dependent natriuretic response to acute sodium load in black salt-sensitive subjects in contrast to salt-resistant subjects. <i>Journal of Hypertension</i> , 1999, 17, 1995-2001.	0.5	36
89	G α 13 protein-coupled dopamine D3 receptor-mediated inhibition of renal NHE3 activity in SHR proximal tubular cells is a PLC-PKC-mediated event. <i>American Journal of Physiology - Renal Physiology</i> , 2004, 287, F1059-F1066.	2.7	36
90	Increased Arterial Blood Pressure and Vascular Remodeling in Mice Lacking Salt-Inducible Kinase 1 (SIK1). <i>Circulation Research</i> , 2015, 116, 642-652.	4.5	36

#	ARTICLE	IF	CITATIONS
91	Safety, Tolerability and Pharmacokinetic Profile of BIA 2-093, a Novel Putative Antiepileptic Agent, during First Administration to Humans. <i>Drugs in R and D</i> , 2003, 4, 269-284.	2.2	35
92	Who volunteers for phase I clinical trials? Influences of anxiety, social anxiety and depressive symptoms on self-selection and the reporting of adverse events. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 575-582.	1.9	35
93	Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study. <i>Clinical Therapeutics</i> , 2010, 32, 179-192.	2.5	35
94	Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: the OPTIPARK open-label study. <i>Translational Neurodegeneration</i> , 2020, 9, 9.	8.0	35
95	Renal amino acid transport systems and essential hypertension. <i>FASEB Journal</i> , 2013, 27, 2927-2938.	0.5	34
96	Dopamine acutely decreases type 3 Na ⁺ /H ⁺ exchanger activity in renal OK cells through the activation of protein kinases A and C signalling cascades. <i>European Journal of Pharmacology</i> , 2004, 488, 51-59.	3.5	33
97	High- and low-affinity transport of L-leucine and L-DOPA by the hetero amino acid exchangers LAT1 and LAT2 in LLC-PK1 renal cells. <i>American Journal of Physiology - Renal Physiology</i> , 2004, 287, F252-F261.	2.7	33
98	Optimization of a Parallel Artificial Membrane Permeability Assay for the Fast and Simultaneous Prediction of Human Intestinal Absorption and Plasma Protein Binding of Drug Candidates: Application to Dibenz[b,f]azepine-5-Carboxamide Derivatives. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 530-540.	3.3	33
99	Role of epithelial ion transports in inflammatory bowel disease. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 310, G460-G476.	3.4	33
100	L-Type Amino Acid Transporters in Two Intestinal Epithelial Cell Lines Function as Exchangers with Neutral Amino Acids. <i>Journal of Nutrition</i> , 2002, 132, 733-738.	2.9	32
101	Na ⁺ -Independent Transporters, LAT-2 and b ⁰ , ⁺ , Exchange L-DOPA with Neutral and Basic Amino Acids in Two Clonal Renal Cell Lines. <i>Journal of Membrane Biology</i> , 2002, 186, 63-80.	2.1	32
102	Bioanalytical chromatographic methods for the determination of catechol-O-methyltransferase inhibitors in rodents and human samples: A review. <i>Analytica Chimica Acta</i> , 2012, 710, 17-32.	5.4	32
103	Development of Blood-Brain Barrier Permeable Nitrocatechol-Based Catechol-O-Methyltransferase Inhibitors with Reduced Potential for Hepatotoxicity. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 7584-7597.	6.4	32
104	Role of type A and B monoamine oxidase on the formation of 3,4-dihydroxyphenylacetic acid (DOPAC) in tissues from the brain of the rat. <i>Neuropharmacology</i> , 1990, 29, 875-879.	4.1	31
105	Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects. <i>Current Medical Research and Opinion</i> , 2010, 26, 1355-1362.	1.9	31
106	Effects of Nebicapone on Levodopa Pharmacokinetics, Catechol-O-methyltransferase Activity, and Motor Fluctuations in Patients with Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2008, 31, 2-18.	0.7	30
107	Pharmacokinetics, brain distribution and plasma protein binding of carbamazepine and nine derivatives: New set of data for predictive in silico ADME models. <i>Epilepsy Research</i> , 2013, 107, 37-50.	1.6	30
108	The effects of eslicarbazepine on persistent Na ⁺ current and the role of the Na ⁺ channel β subunits. <i>Epilepsy Research</i> , 2014, 108, 202-211.	1.6	30

#	ARTICLE	IF	CITATIONS
109	Contemporary Options for the Management of Motor Complications in Parkinson�s Disease: Updated Clinical Review. <i>Drugs</i> , 2019, 79, 593-608.	10.9	30
110	Dopamine-dependent inhibition of jejunal Na ⁺ -K ⁺ -ATPase during high-salt diet in young but not in adult rats. <i>American Journal of Physiology - Renal Physiology</i> , 1998, 275, G1317-G1323.	3.4	29
111	Modulation of insulin transport in rat brain microvessel endothelial cells by an ecto-phosphatase activity. <i>Journal of Cellular Biochemistry</i> , 2002, 84, 389-400.	2.6	29
112	Organ-Specific Overexpression of Renal LAT2 and Enhanced Tubular l-DOPA Uptake Precede the Onset of Hypertension. <i>Hypertension</i> , 2003, 42, 613-618.	2.7	29
113	Increases in intracellular sodium activate transcription and gene expression via the salt-inducible kinase 1 network in an atrial myocyte cell line. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012, 303, H57-H65.	3.2	29
114	Etamicastat, a Novel Dopamine �-Hydroxylase Inhibitor: Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Hypertension. <i>Clinical Therapeutics</i> , 2013, 35, 1983-1996.	2.5	29
115	Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease. <i>Clinical Pharmacology in Drug Development</i> , 2016, 5, 232-240.	1.6	29
116	EFFECTS OF CHEMICAL SYMPATHECTOMY ON DOPAMINE AND NORADRENALINE CONTENT OF THE DOG GASTROINTESTINAL TRACT*. <i>Autonomic and Autacoid Pharmacology</i> , 1985, 5, 189-196.	0.6	28
117	Deamination of newly-formed dopamine in rat renal tissues. <i>British Journal of Pharmacology</i> , 1991, 102, 778-782.	5.4	28
118	Age-related changes in renal expression of oxidant and antioxidant enzymes and oxidative stress markers in male SHR and WKY rats. <i>Experimental Gerontology</i> , 2011, 46, 468-474.	2.8	28
119	Effect of repeated administration of eslicarbazepine acetate on the pharmacokinetics of simvastatin in healthy subjects. <i>Epilepsy Research</i> , 2013, 106, 244-249.	1.6	28
120	Transport of the organic cations gonyautoxin 2/3 epimers, a paralytic shellfish poison toxin, through the human and rat intestinal epitheliums. <i>Toxicol</i> , 2002, 40, 1389-1397.	1.6	27
121	Distinct Signalling Cascades Downstream to G _s -Coupled Dopamine D ₁ -like NHE3 Inhibition in Rat and Opossum Renal Epithelial Cells. <i>Cellular Physiology and Biochemistry</i> , 2004, 14, 91-100.	1.6	27
122	High-salt intake and the renal expression of amino acid transporters in spontaneously hypertensive rats. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 292, F1452-F1463.	2.7	27
123	Evaluation of Eslicarbazepine Acetate on Cardiac Repolarization in a Thorough QT/QTc Study. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 222-233.	2.0	27
124	Effect of moderate liver impairment on the pharmacokinetics of opicapone. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 279-286.	1.9	27
125	Renal and Intestinal Autocrine Monoaminergic Systems: Dopamine Versus 5-hydroxytryptamine. <i>Clinical and Experimental Hypertension</i> , 1997, 19, 43-58.	1.3	26
126	Reduced Urinary Excretion of Dopamine and Metabolites in Chronic Renal Parenchymal Disease. <i>Kidney and Blood Pressure Research</i> , 1998, 21, 59-65.	2.0	26

#	ARTICLE	IF	CITATIONS
127	SALT INTAKE AND SENSITIVITY OF INTESTINAL AND RENAL $\text{Na}^+\text{-K}^+\text{-ATPase}$ TO INHIBITION BY DOPAMINE IN SPONTANEOUS HYPERTENSIVE AND WISTAR-KYOTO RATS. <i>Clinical and Experimental Hypertension</i> , 2000, 22, 455-469.	1.3	26
128	Kinetic inhibitory profile of BIA 3-202, a novel fast tight-binding, reversible and competitive catechol-O-methyltransferase inhibitor. <i>European Journal of Pharmacology</i> , 2003, 460, 163-170.	3.5	26
129	Bioavailability and Bioequivalence of Two Enteric-Coated Formulations of Omeprazole in Fasting and Fed Conditions. <i>Clinical Drug Investigation</i> , 2005, 25, 391-399.	2.2	26
130	H_2O_2 Stimulation of the $\text{Cl}^-/\text{HCO}_3^-$ Exchanger by Angiotensin II and Angiotensin II Type 1 Receptor Distribution in Membrane Microdomains. <i>Hypertension</i> , 2008, 51, 1332-1338.	2.7	26
131	Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects. <i>Fundamental and Clinical Pharmacology</i> , 2009, 23, 509-514.	1.9	26
132	D1-like dopamine receptor activation and natriuresis by nitrocatechol COMT inhibitors. <i>Kidney International</i> , 2001, 59, 1683-1694.	5.2	25
133	Dopamine α -Monooxygenase: Mechanism, Substrates and Inhibitors. <i>Current Enzyme Inhibition</i> , 2009, 5, 27-43.	0.4	25
134	Salt-inducible kinase 1 regulates E-cadherin expression and intercellular junction stability. <i>FASEB Journal</i> , 2012, 26, 3230-3239.	0.5	25
135	Pooled efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal onset seizures: Data from four double-blind placebo-controlled pivotal phase III clinical studies. <i>CNS Neuroscience and Therapeutics</i> , 2017, 23, 961-972.	3.9	25
136	Safety Profile of Opicapone in the Management of Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2019, 9, 733-740.	2.8	25
137	Effect of salt intake on jejunal dopamine, Na^+ , K^+ -ATPase activity and electrolyte transport. <i>Acta Physiologica Scandinavica</i> , 2000, 168, 225-231.	2.2	24
138	The l-3,4-dihydroxyphenylalanine transporter in human and rat epithelial intestinal cells is a type 2 hetero amino acid exchanger. <i>European Journal of Pharmacology</i> , 2002, 441, 127-135.	3.5	24
139	Effect of eslicarbazepine acetate in the corneal kindling progression and the amygdala kindling model of temporal lobe epilepsy. <i>Epilepsy Research</i> , 2014, 108, 212-222.	1.6	24
140	D $_2$ -like receptor-mediated inhibition of $\text{Na}^+\text{-K}^+\text{-ATPase}$ activity is dependent on the opening of K^+ channels. <i>American Journal of Physiology - Renal Physiology</i> , 2002, 283, F114-F123.	2.7	23
141	Synthesis and Biological Evaluation of a Novel Series of α -Ortho-Nitrated Inhibitors of Catechol-O-methyltransferase. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 8070-8078.	6.4	23
142	Reactive oxygen species and the regulation of renal $\text{Na}^+\text{-K}^+\text{-ATPase}$ in opossum kidney cells. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2007, 293, R1764-R1770.	1.8	23
143	Safety, Tolerability, and Pharmacokinetics of Etamicastat, a Novel Dopamine- β -Hydroxylase Inhibitor, in a Rising Multiple-Dose Study in Young Healthy Subjects. <i>Drugs in R and D</i> , 2010, 10, 225-242.	2.2	23
144	Development and validation of an enantioselective liquid-chromatography/tandem mass spectrometry method for the separation and quantification of eslicarbazepine acetate, eslicarbazepine, R-licarbazepine and oxcarbazepine in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2011, 879, 2611-2618.	2.3	23

#	ARTICLE	IF	CITATIONS
145	Does brain 3,4-dihydroxyphenylacetic acid reflect dopamine release?. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 39, 127-129.	2.4	23
146	Opossum kidney (OK) cells in culture synthesize and degrade the natriuretic hormone dopamine: A comparison with rat renal tubular cells. <i>International Journal of Biochemistry and Cell Biology</i> , 1997, 29, 681-688.	2.8	22
147	Neurohormonal activation, the renal dopaminergic system and sodium handling in patients with severe heart failure under vasodilator therapy. <i>Clinical Science</i> , 2001, 100, 557-566.	4.3	22
148	Synthesis, anticonvulsant properties and pharmacokinetic profile of novel 10,11-dihydro-10-oxo-5H-dibenz/b,f/azepine-5-carboxamide derivatives. <i>European Journal of Medicinal Chemistry</i> , 2001, 36, 227-236.	5.5	22
149	Pharmacokinetic?pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide. <i>European Journal of Clinical Pharmacology</i> , 2003, 59, 603-609.	1.9	22
150	Cloning and gene silencing of LAT2, the L-tyrosine, L-tryptophan, and L-dihydroxyphenylalanine (L-DOPA) transporter, in pig renal LLC-PK epithelial cells. <i>FASEB Journal</i> , 2004, 18, 1489-1498.	0.5	22
151	Human Metabolism of Nebicapone (BIA 3-202), a Novel Catechol-O-Methyltransferase Inhibitor: Characterization of in Vitro Glucuronidation. <i>Drug Metabolism and Disposition</i> , 2006, 34, 1856-1862.	3.3	22
152	Carbamazepine and oxcarbazepine, but not eslicarbazepine, enhance excitatory synaptic transmission onto hippocampal CA1 pyramidal cells through an antagonist action at adenosine A1 receptors. <i>Neuropharmacology</i> , 2015, 93, 103-115.	4.1	22
153	Opicapone pharmacokinetics and pharmacodynamics comparison between healthy Japanese and matched white subjects. <i>Clinical Pharmacology in Drug Development</i> , 2016, 5, 150-161.	1.6	22
154	Short-Term vs. Sustained Inhibition of Proximal Tubule Na, K-ATPase Activity by Dopamine: Cellular Mechanisms. <i>Clinical and Experimental Hypertension</i> , 1997, 19, 73-86.	1.3	21
155	Kinetics of Rat Brain and Liver Solubilized Membrane-Bound Catechol-O-Methyltransferase. <i>Archives of Biochemistry and Biophysics</i> , 2000, 384, 361-367.	3.0	21
156	Signaling of short- and long-term regulation of intestinal epithelial type 1 Na ⁺ /H ⁺ exchanger by interferon- β . <i>British Journal of Pharmacology</i> , 2005, 145, 93-103.	5.4	21
157	A Double-blind, Randomized, Placebo and Active-controlled Study of Nebicapone for the Treatment of Motor Fluctuations in Parkinson's Disease. <i>CNS Neuroscience and Therapeutics</i> , 2010, 16, 337-347.	3.9	21
158	Single-dose Tolerability, Pharmacokinetics, and Pharmacodynamics of Etamicastat (BIA 54453), a New Dopamine β -Hydroxylase Inhibitor, in Healthy Subjects. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 156-170.	2.0	21
159	Blood pressure-decreasing effect of etamicastat alone and in combination with antihypertensive drugs in the spontaneously hypertensive rat. <i>Hypertension Research</i> , 2015, 38, 30-38.	2.7	21
160	Discovery of a Potent, Long-Acting, and CNS-Active Inhibitor (BIA 102474) of Fatty Acid Amide Hydrolase. <i>ChemMedChem</i> , 2018, 13, 2177-2188.	3.2	21
161	β -2-Adrenoceptors mediate the effect of dopamine on adult rat jejunal electrolyte transport. <i>European Journal of Pharmacology</i> , 1998, 356, 59-65.	3.5	20
162	The activity of MAO A and B in rat renal cells and tubules. <i>Life Sciences</i> , 1998, 62, 727-737.	4.3	20

#	ARTICLE	IF	CITATIONS
163	Ontogenic aspects of D1 receptor coupling to G proteins and regulation of rat jejunal Na ⁺ , K ⁺ ATPase activity and electrolyte transport. <i>British Journal of Pharmacology</i> , 2000, 129, 573-581.	5.4	20
164	BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation. <i>European Journal of Pharmacology</i> , 2001, 420, 27-32.	3.5	20
165	Regulation of [3 H]MPP ⁺ transport by phosphorylation/dephosphorylation pathways in RBE4 cells: role of ecto-alkaline phosphatase. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2002, 365, 349-356.	3.0	20
166	Overexpression of Na ⁺ /K ⁺ -ATPase Parallels the Increase in Sodium Transport and Potassium Recycling in an In Vitro Model of Proximal Tubule Cellular Ageing. <i>Journal of Membrane Biology</i> , 2006, 212, 163-175.	2.1	20
167	A new approach on the purification of recombinant human soluble catechol-O-methyltransferase from an <i>Escherichia coli</i> extract using hydrophobic interaction chromatography. <i>Journal of Chromatography A</i> , 2008, 1177, 287-296.	3.7	20
168	Repurposing nitrocatechols: 5-Nitro- \pm -cyanocarboxamide derivatives of caffeic acid and caffeic acid phenethyl ester effectively inhibit aggregation of tau-derived hexapeptide AcPHF6. <i>European Journal of Medicinal Chemistry</i> , 2019, 167, 146-152.	5.5	20
169	Pharmacokinetics and Pharmacodynamics of BIA 3-202, a Novel COMT Inhibitor, during First Administration to Humans. <i>Drugs in R and D</i> , 2003, 4, 207-217.	2.2	19
170	Eslicarbazepine Acetate (BIA 2-093). <i>Drugs in R and D</i> , 2005, 6, 253-260.	2.2	19
171	The Chemistry of Catechol-O-Methyltransferase Inhibitors. <i>International Review of Neurobiology</i> , 2010, 95, 119-162.	2.0	19
172	¹⁴ C-Acetylation of Etamicastat, a Reversible Dopamine- β -Hydroxylase Inhibitor. <i>Drug Metabolism and Disposition</i> , 2013, 41, 2081-2086.	3.3	19
173	Blood pressure decrease in spontaneously hypertensive rats following renal denervation or dopamine β -hydroxylase inhibition with etamicastat. <i>Hypertension Research</i> , 2015, 38, 605-612.	2.7	19
174	Assessment of the efficacy and safety of eslicarbazepine acetate in acute mania and prevention of recurrence: Experience from multicentre, double-blind, randomised phase II clinical studies in patients with bipolar disorder I. <i>Journal of Affective Disorders</i> , 2015, 174, 70-82.	4.1	19
175	Elucidation of the Impact of P-glycoprotein and Breast Cancer Resistance Protein on the Brain Distribution of Catechol-O-Methyltransferase Inhibitors. <i>Drug Metabolism and Disposition</i> , 2017, 45, 1282-1291.	3.3	19
176	Enhanced protein kinase C mediated inhibition of renal dopamine synthesis during high sodium intake. <i>Biochemical Pharmacology</i> , 1993, 45, 1791-1800.	4.4	18
177	Involvement of G protein-coupled receptor kinase 4 and 6 in rapid desensitization of dopamine D1 receptor in rat IEC-6 intestinal epithelial cells. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2004, 287, R772-R779.	1.8	18
178	Effects of cyclic hydrostatic pressure on the brain biogenic amines concentrations in the flounder, <i>Platichthys flesus</i> . <i>General and Comparative Endocrinology</i> , 2007, 153, 385-389.	1.8	18
179	Stereoselective disposition of <i>S</i> - and <i>R</i> -eslicarbazepine in mice. <i>Chirality</i> , 2008, 20, 796-804.	2.6	18
180	Safety Profile of Eslicarbazepine Acetate as Add-On Therapy in Adults with Refractory Focal-Onset Seizures: From Clinical Studies to 6 Years of Post-Marketing Experience. <i>Drug Safety</i> , 2017, 40, 1231-1240.	3.2	18

#	ARTICLE	IF	CITATIONS
181	Overflow of endogenous dopamine and 3,4-dihydroxyphenylacetic acid from tissues of the rat brain, elicited by electrical stimulation, depolarization by potassium and activation of carrier-mediated release. <i>Neuropharmacology</i> , 1990, 29, 1151-1159.	4.1	17
182	Activity and Regulation of Na ⁺ -HCO ₃ ⁻ Cotransporter in Immortalized Spontaneously Hypertensive Rat and Wistar-Kyoto Rat Proximal Tubular Epithelial Cells. <i>Hypertension</i> , 2007, 49, 1186-1193.	2.7	17
183	Oxidative stress and α -adrenoceptor-mediated stimulation of the Cl ⁻ /HCO ₃ ⁻ exchanger in immortalized SHR proximal tubular epithelial cells. <i>British Journal of Pharmacology</i> , 2008, 153, 1445-1455.	5.4	17
184	Dosage Form Proportionality and Food Effect of the Final Tablet Formulation of Eslicarbazepine Acetate. <i>Drugs in R and D</i> , 2008, 9, 447-454.	2.2	17
185	Hepatic UDP-Glucuronosyltransferase Is Responsible for Eslicarbazepine Glucuronidation. <i>Drug Metabolism and Disposition</i> , 2011, 39, 1486-1494.	3.3	17
186	Effects of eslicarbazepine acetate on acute and chronic latrunculin A-induced seizures and extracellular amino acid levels in the mouse hippocampus. <i>BMC Neuroscience</i> , 2014, 15, 134.	1.9	17
187	Redefining the strategy for the use of COMT inhibitors in Parkinson's disease: the role of opicapone. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 1019-1033.	2.8	17
188	The O-methylated derivative of L-DOPA, 3-O-methyl-L-DOPA, fails to inhibit neuronal and non-neuronal aromatic L-amino acid decarboxylase. <i>Brain Research</i> , 2000, 863, 293-297.	2.2	16
189	Expression and Characterization of Rat Soluble Catechol-O-methyltransferase Fusion Protein. <i>Protein Expression and Purification</i> , 2001, 23, 106-112.	1.3	16
190	Altered dopaminergic transmission in the anorexic anx/anx mouse striatum. <i>NeuroReport</i> , 2001, 12, 2737-2741.	1.2	16
191	Underexpression of the Na ⁺ -dependent neutral amino acid transporter ASCT2 in the spontaneously hypertensive rat kidney. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2007, 293, R538-R547.	1.8	16
192	Lack of Salt-Inducible Kinase 2 (SIK2) Prevents the Development of Cardiac Hypertrophy in Response to Chronic High-Salt Intake. <i>PLoS ONE</i> , 2014, 9, e95771.	2.5	16
193	Evaluation of opicapone on cardiac repolarization in a thorough QT/QTc study. <i>Clinical Pharmacology in Drug Development</i> , 2015, 4, 454-462.	1.6	16
194	Liver says no: the ongoing search for safe catechol O-methyltransferase inhibitors to replace tolcapone. <i>Drug Discovery Today</i> , 2020, 25, 1846-1854.	6.4	16
195	Efficacy and safety of eslicarbazepine acetate as adjunctive therapy for refractory focal-onset seizures in children: A double-blind, randomized, placebo-controlled, parallel-group, multicenter, phase-III clinical trial. <i>Epilepsy and Behavior</i> , 2020, 105, 106962.	1.7	16
196	Dopamine released from nerve terminals activates prejunctional dopamine receptors in dog mesenteric arterial vessels. <i>British Journal of Pharmacology</i> , 1987, 91, 591-599.	5.4	15
197	Caco-2 cells in culture synthesize and degrade dopamine and 5-hydroxytryptamine: A comparison with rat jejunal epithelial cells. <i>Life Sciences</i> , 1998, 64, 69-81.	4.3	15
198	Pharmacokinetic-Pharmacodynamic Interaction Between BIA 3-202, a Novel COMT Inhibitor, and Levodopa/Carbidopa. <i>Clinical Neuropharmacology</i> , 2004, 27, 17-24.	0.7	15

#	ARTICLE	IF	CITATIONS
199	Intestinal 5-Hydroxytryptamine and Mast Cell Infiltration in Rat Experimental Colitis. <i>Digestive Diseases and Sciences</i> , 2006, 51, 495-501.	2.3	15
200	Dopamine D ₁ -like Receptor-Mediated Inhibition of Cl ⁻ /HCO ₃ ⁻ Exchanger Activity in Rat Intestinal Epithelial IEC-6 Cells is Regulated by G Protein-Coupled Receptor Kinase 6 (GRK 6). <i>Cellular Physiology and Biochemistry</i> , 2006, 18, 347-360.	1.6	15
201	Pharmacokinetics and Tolerability of Etamicastat Following Single and Repeated Administration in Elderly Versus Young Healthy Male Subjects: An Open-Label, Single-Center, Parallel-Group Study. <i>Clinical Therapeutics</i> , 2011, 33, 776-791.	2.5	15
202	A chiral liquid chromatography method for the simultaneous determination of oxcarbazepine, eslicarbazepine, <i>eslicarbazepine</i> and other new chemical derivatives BIA 2024, BIA 059 and BIA 265, in mouse plasma and brain. <i>Biomedical Chromatography</i> , 2012, 26, 384-392.	1.7	15
203	A chiral HPLC-UV method for the quantification of dibenz[b,f]azepine-5-carboxamide derivatives in mouse plasma and brain tissue: Eslicarbazepine acetate, carbamazepine and main metabolites. <i>Journal of Separation Science</i> , 2011, 34, 1391-1401.	2.5	15
204	Inhibitory effect of phenolic compounds from grape seeds (<i>Vitis vinifera</i> L.) on the activity of angiotensin I converting enzyme. <i>LWT - Food Science and Technology</i> , 2013, 54, 265-270.	5.2	15
205	Evidence for dopaminergic co-transmission in dog mesenteric arterial vessels. <i>British Journal of Pharmacology</i> , 1988, 95, 218-224.	5.4	14
206	Effects of sympathetic denervation on liver fibroblasts: prevention by adenosine. <i>Autonomic and Autacoid Pharmacology</i> , 1990, 10, 181-189.	0.6	14
207	The renal dopaminergic system, neurohumoral activation, and sodium handling in heart failure. <i>American Heart Journal</i> , 2002, 143, 391-397.	2.7	14
208	Dopamine-induced inhibition of Na ⁺ -K ⁺ -ATPase activity requires integrity of actin cytoskeleton in opossum kidney cells. <i>Acta Physiologica Scandinavica</i> , 2002, 175, 93-101.	2.2	14
209	Catechol-O-methyltransferase Inhibition in Erythrocytes and Liver by BIA 3-202 (1-[3,4-dihydroxy-5-nitrophenyl]-2-phenyl-ethanone). <i>Basic and Clinical Pharmacology and Toxicology</i> , 2003, 92, 272-278.	0.0	14
210	Intestinal Na ⁺ -K ⁺ -ATPase activity and molecular events downstream of interferon- β receptor stimulation. <i>British Journal of Pharmacology</i> , 2004, 142, 1281-1292.	5.4	14
211	Effect of Saline Load and Metoclopramide on the Renal Dopaminergic System in Patients with Heart Failure and Healthy Controls. <i>Journal of Cardiovascular Pharmacology</i> , 2005, 45, 197-203.	1.9	14
212	Interferon- β -induced STAT1-mediated membrane retention of NHE1 and associated proteins ezrin, radixin and moesin in HT-29 cells. <i>Biochemical Pharmacology</i> , 2005, 70, 1312-1319.	4.4	14
213	Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 540-553.	2.4	14
214	Acute Hypotensive, Natriuretic, and Hormonal Effects of Nifedipine in Salt-Sensitive and Salt-Resistant Black Normotensive and Hypertensive Subjects. <i>Journal of Cardiovascular Pharmacology</i> , 1999, 34, 346-353.	1.9	14
215	A comparison of the action of the endothelium-derived relaxant factor and the inhibitory factor from the bovine retractor penis on rabbit aortic smooth muscle. <i>British Journal of Pharmacology</i> , 1986, 87, 175-181.	5.4	13
216	Comparative study on sodium transport and Na ⁺ ,K ⁺ -ATPase activity in Caco-2 and rat jejunal epithelial cells. <i>Life Sciences</i> , 2001, 69, 1969-1981.	4.3	13

#	ARTICLE	IF	CITATIONS
217	Na ⁺ /H ⁺ Exchanger Activity and Dopamine D ₁ -Like Receptor Function in two Opossum Kidney Cell Clonal Sublines. <i>Cellular Physiology and Biochemistry</i> , 2002, 12, 259-268.	1.6	13
218	Regulation of apical transporter of L-DOPA in human intestinal Caco-2 cells. <i>Acta Physiologica Scandinavica</i> , 2002, 175, 103-111.	2.2	13
219	Pharmacokinetic and Pharmacodynamic Profiles of BIA 3-202, a Novel Catechol-O-Methyltransferase (COMT) Inhibitor, during Multiple-Dose Administration to Healthy Subjects. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 1350-1360.	2.0	13
220	Oxidative stress plays a permissive role in β -adrenoceptor-mediated events in immortalized SHR proximal tubular epithelial cells. <i>Molecular and Cellular Biochemistry</i> , 2008, 315, 31-39.	3.1	13
221	Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: A single-center, phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects. <i>Clinical Therapeutics</i> , 2009, 31, 2258-2271.	2.5	13
222	Loss of oxidative stress tolerance in hypertension is linked to reduced catalase activity and increased c-Jun NH2-terminal kinase activation. <i>Free Radical Biology and Medicine</i> , 2013, 56, 112-122.	2.9	13
223	Safety, Tolerability and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy in Patients Aged ≥ 65 Years with Focal Seizures. <i>Drugs and Aging</i> , 2018, 35, 1109-1117.	2.7	13
224	Effects of eslicarbazepine on slow inactivation processes of sodium channels in dentate gyrus granule cells. <i>Epilepsia</i> , 2018, 59, 1492-1506.	5.1	13
225	Actin cytoskeleton, tubular sodium and the renal synthesis of dopamine. <i>Biochemical Pharmacology</i> , 1992, 44, 1883-1886.	4.4	12
226	Studies on the Nature of the Antagonistic Actions of Dopamine and 5-Hydroxytryptamine in Renal Tissues. <i>Hypertension Research</i> , 1995, 18, S47-S51.	2.7	12
227	Assessment of renal dopaminergic system activity during the recovery of renal function in human kidney transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 1997, 12, 2667-2672.	0.7	12
228	RENAL DOPAMINERGIC MECHANISMS IN RENAL PARENCHYMAL DISEASES, HYPERTENSION, AND HEART FAILURE. <i>Clinical and Experimental Hypertension</i> , 2000, 22, 251-268.	1.3	12
229	Neurohormonal activation, the renal dopaminergic system and sodium handling in patients with severe heart failure under vasodilator therapy. <i>Clinical Science</i> , 2001, 100, 557.	4.3	12
230	INTESTINAL DOPAMINERGIC ACTIVITY IN OBESE AND LEAN ZUCKER RATS: RESPONSE TO HIGH SALT INTAKE. <i>Clinical and Experimental Hypertension</i> , 2002, 24, 383-396.	1.3	12
231	Expression and function of sodium transporters in two opossum kidney cell clonal sublines. <i>American Journal of Physiology - Renal Physiology</i> , 2002, 283, F73-F85.	2.7	12
232	BIA 3-202, a Novel Catechol-O-Methyltransferase Inhibitor, Reduces the Peripheral O-Methylation of L-DOPA and Enhances Its Availability to the Brain. <i>Pharmacology</i> , 2003, 68, 29-37.	2.2	12
233	Disposition of eslicarbazepine acetate in the mouse after oral administration. <i>Fundamental and Clinical Pharmacology</i> , 2008, 22, 529-536.	1.9	12
234	Age-related changes in the renal dopaminergic system and expression of renal amino acid transporters in WKY and SHR rats. <i>Mechanisms of Ageing and Development</i> , 2011, 132, 298-304.	4.6	12

#	ARTICLE	IF	CITATIONS
235	Eslicarbazepine acetate exposure in pregnant women with epilepsy. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2018, 58, 72-74.	2.0	12
236	A comparative study on the synthesis of dopamine in the human, dog and rat kidney. <i>Acta Physiologica Scandinavica</i> , 1993, 148, 347-351.	2.2	11
237	Renal tubular dopamine outward transfer during Na ⁺ -H ⁺ exchange activation by $\hat{1}\pm 1$ - and $\hat{1}\pm 2$ -adrenoceptor agonists. <i>British Journal of Pharmacology</i> , 1993, 109, 569-576.	5.4	11
238	Kinetic study of the tubular dopamine outward transporter in the rat and dog kidney. <i>British Journal of Pharmacology</i> , 1993, 109, 577-580.	5.4	11
239	Uptake of l-3,4-dihydroxyphenylalanine and dopamine formation in cultured renal epithelial cells. <i>Biochemical Pharmacology</i> , 1997, 54, 1037-1046.	4.4	11
240	Heart failure, aging, and renal synthesis of dopamine. <i>American Journal of Kidney Diseases</i> , 2001, 38, 502-509.	1.9	11
241	Effects of cyclic and constant hydrostatic pressure on norepinephrine and epinephrine levels in the brain of flounder. <i>Journal of Fish Biology</i> , 2006, 68, 1300-1307.	1.6	11
242	Genomic regulation of intestinal amino acid transporters by aldosterone. <i>Molecular and Cellular Biochemistry</i> , 2008, 313, 1-10.	3.1	11
243	Enantioselective Assay for Therapeutic Drug Monitoring of Eslicarbazepine Acetate: No Interference With Carbamazepine and Its Metabolites. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 512-516.	2.0	11
244	Renal aging in WKY rats: Changes in Na ⁺ ,K ⁺ -ATPase function and oxidative stress. <i>Experimental Gerontology</i> , 2010, 45, 977-983.	2.8	11
245	Characterization of the interaction of the novel antihypertensive etamicastat with human dopamine- $\hat{1}^2$ -hydroxylase: Comparison with nopicastat. <i>European Journal of Pharmacology</i> , 2015, 751, 50-58.	3.5	11
246	Polyamine Modulation of Anticonvulsant Drug Response: A Potential Mechanism Contributing to Pharmacoresistance in Chronic Epilepsy. <i>Journal of Neuroscience</i> , 2018, 38, 5596-5605.	3.6	11
247	Effects of nopicastat upon dopamine- $\hat{1}^2$ -hydroxylase activity and dopamine and norepinephrine levels in the rat left ventricle, kidney, and adrenal gland. <i>Clinical and Experimental Hypertension</i> , 2020, 42, 118-125.	1.3	11
248	Preclinical pharmacological evaluation of the fatty acid amide hydrolase inhibitor BIA 10 $\hat{2}$ 474. <i>British Journal of Pharmacology</i> , 2020, 177, 2123-2142.	5.4	11
249	Safety, Tolerability, and Pharmacokinetics of FAAH Inhibitor BIA 10 $\hat{2}$ 474: A Double-blind, Randomized, Placebo-controlled Study in Healthy Volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 391-403.	4.7	11
250	High sodium intake increases the urinary excretion of L-3,4-dihydroxyphenylalanine but fails to alter the urinary excretion of dopamine and amine metabolites in wistar rats. <i>General Pharmacology</i> , 1996, 27, 1421-1427.	0.7	10
251	Evidence for the involvement of P-glycoprotein on the extrusion of taken up L-DOPA in cyclosporine A treated LLC-PK 1 cells. <i>British Journal of Pharmacology</i> , 1998, 123, 13-22.	5.4	10
252	Transport of [³ H]MPP + in an immortalized rat brain microvessel endothelial cell line (RBE 4). <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2001, 363, 1-10.	3.0	10

#	ARTICLE	IF	CITATIONS
253	Regional intestinal adaptations in Na ⁺ ,K ⁺ -ATPase in experimental colitis and the contrasting effects of interferon-gamma. <i>Acta Physiologica Scandinavica</i> , 2005, 183, 191-199.	2.2	10
254	Upregulation of apical NHE3 in renal OK cells overexpressing the rodent α 1-subunit of the Na ⁺ pump. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2006, 290, R1142-R1150.	1.8	10
255	Species differences in pharmacokinetic and pharmacodynamic properties of nebicapone. <i>Biochemical Pharmacology</i> , 2009, 78, 1043-1051.	4.4	10
256	Protein cytoskeleton and overexpression of Na ⁺ ,K ⁺ -ATPase in opossum kidney cells. <i>Journal of Cellular Physiology</i> , 2009, 221, 318-324.	4.1	10
257	Binding of licarbazepine enantiomers to mouse and human plasma proteins. <i>Biopharmaceutics and Drug Disposition</i> , 2010, 31, 362-366.	1.9	10
258	Influence of titration schedule and maintenance dose on the tolerability of adjunctive eslicarbazepine acetate: An integrated analysis of three randomized placebo-controlled trials. <i>Epilepsy Research</i> , 2018, 139, 1-8.	1.6	10
259	Acute salt loading induces sympathetic nervous system overdrive in mice lacking salt-inducible kinase 1 (SIK1). <i>Hypertension Research</i> , 2019, 42, 1114-1124.	2.7	10
260	Population Pharmacokinetic-Pharmacodynamic Modeling for Propofol Anesthesia Guided by the Bispectral Index (BIS). <i>Journal of Clinical Pharmacology</i> , 2019, 60, 617.	2.0	10
261	Amino acid and metal content of <i>Crassostrea gigas</i> shell infested by <i>Polydora</i> sp. in the prismatic layer insoluble matrix and blister membrane. <i>Aquatic Living Resources</i> , 1996, 9, 179-186.	1.2	9
262	Dopamine D2-like receptors in the rat kidney: Effect of denervation. <i>European Journal of Pharmacology</i> , 1997, 334, 233-240.	3.5	9
263	OPOSSUM KIDNEY CELLS TAKE UP L-DOPA THROUGH AN ORGANIC CATION POTENTIAL-DEPENDENT AND PROTON-INDEPENDENT TRANSPORTER. <i>Cell Biology International</i> , 1997, 21, 249-255.	3.0	9
264	Expression and function of LAT1, a neutral amino acid exchanger, in renal porcine epithelial cell line LLC-PK1. <i>Acta Physiologica Scandinavica</i> , 2005, 185, 71-78.	2.2	9
265	Increases in transepithelial vectorial Na ⁺ transport facilitates Na ⁺ -dependent L-DOPA transport in renal OK cells. <i>Life Sciences</i> , 2006, 79, 723-729.	4.3	9
266	Regulation of amino acid transporters in the rat remnant kidney. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 2058-2067.	0.7	9
267	An HPLC-DAD method for the simultaneous quantification of opicapone (BIA 9-1067) and its active metabolite in human plasma. <i>Analyst</i> , 2013, 138, 2463.	3.5	9
268	Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nopicastat. <i>Xenobiotica</i> , 2015, 45, 828-839.	1.1	9
269	Sustained high blood pressure reduction with etamicastat, a peripheral selective dopamine β -hydroxylase inhibitor. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 207-216.	2.3	9
270	The effect of PRR ligands on the membrane potential of intestinal epithelial cells. <i>Pharmacological Reports</i> , 2017, 69, 978-984.	3.3	9

#	ARTICLE	IF	CITATIONS
271	Antihypertensive effect of etamicastat in dopamine D2 receptor-deficient mice. <i>Hypertension Research</i> , 2018, 41, 489-498.	2.7	9
272	In vitro assessment of the interactions of dopamine β -hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 117, 35-40.	4.0	9
273	Effects of adjunctive eslicarbazepine acetate on serum lipids in patients with partial-onset seizures: Impact of concomitant statins and enzyme-inducing antiepileptic drugs. <i>Epilepsy Research</i> , 2018, 141, 83-89.	1.6	9
274	Pharmacodynamic evaluation of novel Catechol-O-methyltransferase inhibitors. <i>European Journal of Pharmacology</i> , 2019, 847, 53-60.	3.5	9
275	Analysis of cutaneous allergic reactions in clinical trials of eslicarbazepine acetate. <i>Acta Neurologica Scandinavica</i> , 2020, 141, 397-404.	2.1	9
276	A COMPARATIVE STUDY ON THE SYNTHESIS OF THE NATRIURETIC HORMONE DOPAMINE IN OK AND LLC-PK1 CELLS. <i>Cell Biology International</i> , 1996, 20, 539-544.	3.0	8
277	Metabolism of 10,11-dihydro-10-hydroxyimino-5H-dibenz[b, e]azepine-5-carboxamide, a potent anti-epileptic drug. <i>Xenobiotica</i> , 2002, 32, 131-140.	1.1	8
278	Organ specific underexpression renal of Na ⁺ -dependent B0AT1 in the SHR correlates positively with overexpression of NHE3 and salt intake. <i>Molecular and Cellular Biochemistry</i> , 2007, 306, 9-18.	3.1	8
279	H2O2 stimulates Cl ⁻ /HCO ₃ ⁻ exchanger activity through oxidation of thiol groups in immortalized SHR renal proximal tubular epithelial cells. <i>Journal of Cellular Biochemistry</i> , 2011, 112, 3660-3665.	2.6	8
280	Short- and Long-Term Regulation of Intestinal Na ⁺ /H ⁺ Exchange Activity Associated with TLR2 Receptor Activation Is Independent of Nuclear Factor- κ B Signaling. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 346, 453-464.	2.5	8
281	Evaluation of neurotoxic and neuroprotective pathways affected by antiepileptic drugs in cultured hippocampal neurons. <i>Toxicology in Vitro</i> , 2013, 27, 2193-2202.	2.4	8
282	Opicapone versus placebo in the treatment of Parkinson's disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone) Tj ETQ0 0 0.8 BT / Overlock 10 T	0.8	7
283	Fibroblasts and Sympathetic Innervation of Blood Vessels. <i>Journal of Vascular Research</i> , 1985, 22, 278-285.	1.4	7
284	Further evidence for a noradrenaline-independent storage of dopamine in the dog kidney. <i>Autonomic and Autacoid Pharmacology</i> , 1988, 8, 127-134.	0.6	7
285	l-3,4-Dihydroxyphenylalanine (l-DOPA) secreted by oyster (<i>Crassostrea gigas</i>) mantle cells: functional aspects. <i>Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology</i> , 1998, 120, 709-713.	1.6	7
286	Renal synthesis of dopamine in asymptomatic post-infarction left ventricular systolic dysfunction. <i>Clinical Science</i> , 2000, 99, 195-200.	4.3	7
287	Salt intake and intestinal dopaminergic activity in adult and old Fischer 344 rats. <i>Life Sciences</i> , 2001, 69, 1957-1968.	4.3	7
288	Crystallization and preliminary crystallographic characterization of catechol-O-methyltransferase in complex with its cosubstrate and an inhibitor. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2001, 57, 906-908.	2.5	7

#	ARTICLE	IF	CITATIONS
289	Dopamine D2-like receptor-mediated opening of K ⁺ channels in opossum kidney cells. <i>British Journal of Pharmacology</i> , 2003, 138, 968-976.	5.4	7
290	Salt sensitivity of blood pressure in patients with psoriasis on ciclosporin therapy. <i>British Journal of Dermatology</i> , 2005, 152, 773-776.	1.5	7
291	Crystallization and preliminary X-ray diffraction studies of a catechol-O-methyltransferase/inhibitor complex. <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2005, 61, 118-120.	0.7	7
292	Short-term effect on intestinal epithelial Na ⁺ /H ⁺ exchanger by Gi \pm 1,2-coupled 5-HT _{1A} and Gq/11-coupled 5-HT ₂ receptors. <i>Life Sciences</i> , 2007, 81, 560-569.	4.3	7
293	Short-term regulation of the Cl ⁻ /HCO ₃ ⁻ exchanger in immortalized SHR proximal tubular epithelial cells. <i>Biochemical Pharmacology</i> , 2008, 75, 2224-2233.	4.4	7
294	Increased responsiveness to JNK1/2 mediates the enhanced H ₂ O ₂ -induced stimulation of Cl ⁻ /HCO ₃ ⁻ exchanger activity in immortalized renal proximal tubular epithelial cells from the SHR. <i>Biochemical Pharmacology</i> , 2010, 80, 913-919.	4.4	7
295	Effect of Food on the Pharmacokinetic Profile of Etamicastat (BIA 5-453). <i>Drugs in R and D</i> , 2011, 11, 127-136.	2.2	7
296	Long-term regulation of Na ⁺ ,K ⁺ -ATPase in opossum kidney cells by ouabain. <i>Journal of Cellular Physiology</i> , 2011, 226, 2391-2397.	4.1	7
297	Identification of SLC26A transporters involved in the Cl ⁻ /HCO ₃ ⁻ exchange in proximal tubular cells from WKY and SHR. <i>Life Sciences</i> , 2013, 93, 435-440.	4.3	7
298	Etamicastat, a new dopamine- β -hydroxylase inhibitor, pharmacodynamics and metabolism in rat. <i>European Journal of Pharmacology</i> , 2014, 740, 285-294.	3.5	7
299	Carbamazepine aggravates absence seizures in two dedicated mouse models. <i>Pharmacological Reports</i> , 2015, 67, 986-995.	3.3	7
300	Amine neurotransmitters, inflammation and epithelial sodium transport. <i>Experimental Physiology</i> , 2016, 101, 459-464.	2.0	7
301	Long-term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: An open-label extension study. <i>Epilepsia</i> , 2020, 61, 2129-2141.	5.1	7
302	Catechol-O-Methyltransferase Inhibitors: Present Problems and Relevance of the New Ones. <i>RSC Drug Discovery Series</i> , 2013, , 83-109.	0.3	7
303	The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II. <i>Frontiers in Neurology</i> , 2021, 12, 754016.	2.4	7
304	Ca ²⁺ /calmodulin mediated pathways regulate the uptake of L-DOPA in mouse neuroblastoma neuro 2A cells. <i>Life Sciences</i> , 2000, 67, 3209-3220.	4.3	6
305	Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 961-966.	1.9	6
306	Human disposition, metabolism and excretion of etamicastat, a reversible, peripherally selective dopamine β -hydroxylase inhibitor. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 1017-1026.	2.4	6

#	ARTICLE	IF	CITATIONS
307	Short- and long-term regulation of intestinal Na ⁺ /H ⁺ exchange by Toll-like receptors TLR4 and TLR5. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 309, G703-G715.	3.4	6
308	Development of a liquid chromatography assay for the determination of opicapone and BIA 9�1079 in rat matrices. <i>Biomedical Chromatography</i> , 2016, 30, 312-322.	1.7	6
309	A single- and multiple-dose study to investigate the pharmacokinetics and pharmacodynamics of opicapone, a novel COMT inhibitor, in rat. <i>Neuropharmacology</i> , 2017, 125, 146-155.	4.1	6
310	Effects of zamicastat treatment in a genetic model of salt-sensitive hypertension and heart failure. <i>European Journal of Pharmacology</i> , 2019, 842, 125-132.	3.5	6
311	<i>In vitro</i> and <i>in vivo</i> anti�epileptic efficacy of eslicarbazepine acetate in a mouse model of KCNQ2-related self-limited epilepsy. <i>British Journal of Pharmacology</i> , 2022, 179, 84-102.	5.4	6
312	Salt-inducible kinases: new players in pulmonary arterial hypertension?. <i>Trends in Pharmacological Sciences</i> , 2022, 43, 806-819.	8.7	6
313	Nonneuronal Dopamine. <i>Advances in Pharmacology</i> , 1997, 42, 866-869.	2.0	5
314	Rat Liver Catechol-O-Methyltransferase Kinetics and Assay Methodology. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 1998, 13, 473-483.	0.5	5
315	Response of jejunal Na ⁺ , K ⁺ ATPase to 5�hydroxytryptamine in young and adult rats: Effect of fasting and refeeding. <i>Acta Physiologica Scandinavica</i> , 2000, 169, 167-172.	2.2	5
316	Chronopharmacology of nebicapone, a new catechol-O-methyltransferase inhibitor. <i>Current Medical Research and Opinion</i> , 2010, 26, 1097-1108.	1.9	5
317	In-vivo evaluation of prolonged release bilayer tablets of anti-Parkinson drugs in G�ttingen minipigs. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 63, 780-785.	2.4	5
318	Pharmacokinetics of opicapone, a third-generation COMT inhibitor, after single and multiple oral administration: A comparative study in the rat. <i>Toxicology and Applied Pharmacology</i> , 2017, 323, 9-15.	2.8	5
319	Cardiometabolic and Inflammatory Benefits of Sympathetic Down-Regulation with Zamicastat in Aged Spontaneously Hypertensive Rats. <i>ACS Pharmacology and Translational Science</i> , 2019, 2, 353-360.	4.9	5
320	Regulatory safety pharmacology evaluation of BIA 10-2474. <i>Journal of Pharmacological and Toxicological Methods</i> , 2020, 102, 106677.	0.7	5
321	Antagonistic modulation of SIK1 and SIK2 isoforms in high blood pressure and cardiac hypertrophy triggered by high-salt intake. <i>Clinical and Experimental Hypertension</i> , 2021, 43, 1-8.	1.3	5
322	Opicapone as an Add-on to Levodopa in Patients with Parkinson�s Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial. <i>Neurology and Therapy</i> , 2022, 11, 1409-1425.	3.2	5
323	A study on the neuronal and non-neuronal stores of dopamine in rat and rabbit kidney. <i>Pharmacological Research</i> , 1992, 26, 161-171.	7.1	4
324	Preferential decarboxylation of l-threo-3,4-dihydroxyphenylserine in rat renal tissues. <i>General Pharmacology</i> , 1993, 24, 75-81.	0.7	4

#	ARTICLE	IF	CITATIONS
325	Ontogeny of the cell outward dopamine transporter in canine renal tissues. <i>Fundamental and Clinical Pharmacology</i> , 1995, 9, 255-262.	1.9	4
326	P-glycoprotein phosphorylation/dephosphorylation and cellular accumulation of L-DOPA in LLC-GA5 Col300 cells. <i>Autonomic and Autacoid Pharmacology</i> , 1999, 19, 173-179.	0.6	4
327	Renal synthesis of dopamine in asymptomatic post-infarction left ventricular systolic dysfunction. <i>Clinical Science</i> , 2000, 99, 195.	4.3	4
328	Differential substrate specificity of monoamine oxidase in the rat heart and renal cortex. <i>Life Sciences</i> , 2003, 73, 955-967.	4.3	4
329	Renal Dopamine and Salt Sensitivity of Blood Pressure in IgA Nephropathy. <i>Kidney and Blood Pressure Research</i> , 2004, 27, 78-87.	2.0	4
330	Overexpression of Non-Functional LAT1/4F2hc in Renal Proximal Tubular Epithelial Cells from the Spontaneous Hypertensive Rat. <i>Cellular Physiology and Biochemistry</i> , 2007, 20, 535-548.	1.6	4
331	Pharmacokinetic-Pharmacodynamic Interaction between Nebicapone, a Novel Catechol-O-Methyltransferase Inhibitor, and Controlled-Release Levodopa/Carbidopa 200Âmg/50Âmg. <i>Drugs in R and D</i> , 2008, 9, 435-446.	2.2	4
332	Pharmacokinetics, Disposition, and Metabolism of [14C]-Nebicapone in Humans. <i>Drug Metabolism Letters</i> , 2010, 4, 149-162.	0.8	4
333	Age-dependent effect of ouabain on renal Na ⁺ ,K ⁺ -ATPase. <i>Life Sciences</i> , 2011, 88, 719-724.	4.3	4
334	Pharmacological Profile of Opicapone in Wistar rat. , 2014, , 83.		4
335	Cardiac safety profile of etamicastat, a novel peripheral selective dopamine- β -hydroxylase inhibitor in non-human primates, human young and elderly healthy volunteers and hypertensive patients. <i>IJC Metabolic & Endocrine</i> , 2015, 7, 10-24.	0.5	4
336	Inhibition of catechol-O-methyltransferase in the cynomolgus monkey by opicapone after acute and repeated administration. <i>Neuropharmacology</i> , 2018, 143, 282-288.	4.1	4
337	Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by levodopa in cynomolgus monkeys. <i>European Journal of Pharmacology</i> , 2021, 892, 173742.	3.5	4
338	Complex effects of eslicarbazepine on inhibitory micro networks in chronic experimental epilepsy. <i>Epilepsia</i> , 2021, 62, 542-556.	5.1	4
339	Safety of Eslicarbazepine Acetate in Elderly Versus Non-Elderly Patients with Focal Seizures: From Pooled Data of Clinical Studies to 8 Years of Post-Marketing Experience. <i>Drug Safety</i> , 2021, 44, 1099-1107.	3.2	4
340	Opicapone in UK clinical practice: effectiveness, safety and cost analysis in patients with Parkinson's disease. <i>Neurodegenerative Disease Management</i> , 2022, 12, 77-91.	2.2	4
341	Metabolism and disposition of opicapone in the rat and metabolic enzymes phenotyping. <i>Pharmacology Research and Perspectives</i> , 2022, 10, e00891.	2.4	4
342	Absorption, metabolism and excretion of opicapone in human healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2022, , .	2.4	4

#	ARTICLE	IF	CITATIONS
343	Relaxant effects of \pm human atrial natriuretic peptide on venous smooth muscle. <i>Autonomic and Autacoid Pharmacology</i> , 1991, 11, 139-145.	0.6	3
344	Nature and kinetic characteristics of L-DOPA uptake in rat renal proximal tubules. <i>Amino Acids</i> , 1995, 8, 265-270.	2.7	3
345	Competitive and non-competitive inhibition of l-3,4-dihydroxyphenylalanine uptake in Opossum kidney cells. <i>European Journal of Pharmacology</i> , 1997, 332, 219-225.	3.5	3
346	The dopamine antagonist Sch 23390 reverses dizocilpine-induced blockade of cocaine sensitization. <i>Neuropharmacology</i> , 2000, 39, 1645-1652.	4.1	3
347	INHIBITION OF CALCIUM-INDEPENDENT LUMINAL UPTAKE OF L-DOPA BY CALMODULIN ANTAGONISTS IN IMMORTALIZED RAT CAPILLARY CEREBRAL ENDOTHELIAL CELLS. <i>Cell Biology International</i> , 2001, 25, 245-252.	3.0	3
348	Apical and basolateral 4F2hc and the amino acid exchange of L-DOPA in renal LLC-PK1 cells. <i>Amino Acids</i> , 2005, 29, 213-219.	2.7	3
349	The Role of Socioeconomic Conditions and Psychological Factors in the Willingness to Volunteer for Phase I Studies. <i>Pharmaceutical Medicine</i> , 2008, 22, 367-374.	1.9	3
350	LAT1 overexpression and function compensates downregulation of ASCT2 in an in vitro model of renal proximal tubule cell ageing. <i>Molecular and Cellular Biochemistry</i> , 2011, 349, 107-116.	3.1	3
351	Long-term food restriction attenuates age-related changes in the expression of renal aldosterone-sensitive sodium transporters in Wistar-Kyoto rats: A comparison with SHR. <i>Experimental Gerontology</i> , 2012, 47, 644-653.	2.8	3
352	Synthesis and structure-activity relationships of ionizable 1,3,4-oxadiazol-2(3 <i>H</i>)-ones as peripherally selective FAAH inhibitors with improved aqueous solubility. <i>Pure and Applied Chemistry</i> , 2016, 88, 341-347.	1.9	3
353	Comparative analysis of the safety and tolerability of eslicarbazepine acetate in older (≥ 60 years) and younger (18-59 years) adults. <i>Epilepsy Research</i> , 2021, 169, 106478.	1.6	3
354	Non-clinical toxicology evaluation of BIA 10-2474. <i>Critical Reviews in Toxicology</i> , 2021, 51, 65-75.	3.9	3
355	Regulation of Renal LAT2 and 4F2hc Expression by Aldosterone. <i>Journal of Epithelial Biology & Pharmacology</i> , 2009, 2, 36-43.	1.2	3
356	Renal dopaminergic system in nephrotic syndrome and after remission. <i>Nephrology Dialysis Transplantation</i> , 1998, 13, 2559-2562.	0.7	2
357	Role of H ₂ O ₂ on the kinetics of low-affinity high-capacity Na ⁺ -dependent alanine transport in SHR proximal tubular epithelial cells. <i>Biochemical and Biophysical Research Communications</i> , 2010, 398, 553-558.	2.1	2
358	Bioequivalence of Eslicarbazepine Acetate from Two Different Sources of its Active Product Ingredient in Healthy Subjects. <i>Drugs in R and D</i> , 2013, 13, 137-143.	2.2	2
359	Cardiovascular safety pharmacology profile of etamicastat, a novel peripheral selective dopamine- β -hydroxylase inhibitor. <i>European Journal of Pharmacology</i> , 2015, 750, 98-107.	3.5	2
360	The role of salt-inducible kinases on the modulation of renal and intestinal Na ⁺ ,K ⁺ -ATPase activity during short- and long-term high-salt intake. <i>European Journal of Pharmacology</i> , 2021, 904, 174153.	3.5	2

#	ARTICLE	IF	CITATIONS
361	EVALUATION OF THE POTENCY AND SELECTIVITY OF THE NOVEL FAAH INHIBITOR BIA 1042474 IN COMPARISON WITH PF04457845 AND JNJ42165279. <i>FASEB Journal</i> , 2018, 32, 692.14.	0.5	2
362	Outflow of dopamine and noradrenaline originating from L-DOPA and in rat renal tissues. <i>General Pharmacology</i> , 1994, 25, 879-885.	0.7	1
363	Isosorbide 5-mononitrate reverses high blood pressure in methyl ester treated rats. <i>General Pharmacology</i> , 1994, 25, 1329-1336.	0.7	1
364	88 Unusual pattern of β^2 -phenylethylamine deamination in the rat heart. <i>Biochemical Society Transactions</i> , 1997, 25, S622-S622.	3.4	1
365	Relative Bioavailability of Two Enteric-Coated Formulations of Omeprazole following Repeated Doses in Healthy Volunteers. <i>Clinical Drug Investigation</i> , 2001, 21, 203-210.	2.2	1
366	Short- and long-term regulation of intestinal Na ⁺ /H ⁺ exchanger by IFN- γ in Caco-2 cells. <i>Gastroenterology</i> , 2003, 124, A313.	1.3	1
367	Interpersonal Values of Healthy Subjects Who Volunteer for Phase I Clinical Trials. <i>Pharmaceutical Medicine</i> , 2009, 23, 299-303.	1.9	1
368	Comments on the Eslicarbazepine Acetate Section of the Article "Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications". <i>Pharmaceuticals</i> , 2010, 3, 3629-3632.	3.8	1
369	Effect of Opicapone, a New Catechol-O-Methyltransferase Inhibitor, in Levodopa Pharmacokinetics in the Cynomolgous Monkey. , 2014, , 79.		1
370	Bioelectrical impedance analysis of body composition for the anesthetic induction dose of propofol in older patients. <i>BMC Anesthesiology</i> , 2019, 19, 180.	1.8	1
371	Ouabain induced hypertension and Na ⁺ ,K ⁺ ATPase in Wistar rats. <i>FASEB Journal</i> , 2007, 21, A1363.	0.5	1
372	DISTRIBUTION, METABOLISM AND ELIMINATION OF OPICAPONE IN THE RAT AND NON-HUMAN PRIMATE. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO4-1-28.	0.0	1
373	DISTRIBUTION, METABOLISM AND ELIMINATION OF BIA 1042474 IN THE RAT. <i>FASEB Journal</i> , 2018, 32, 833.3.	0.5	1
374	In vitro Species Different Metabolism and CYP Phenotyping of Zamicastat. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.5	1
375	Opicapone Use in Clinical Practice across Germany: A Sub-Analysis of the OPTIPARK Study in Parkinson's Disease Patients with Motor Fluctuations. <i>European Neurology</i> , 2022, , 1-9.	1.4	1
376	l-3,4-dihydroxyphenylalanine and l-5-hydroxytryptophan share the same transporter in Opossum kidney cells. <i>International Journal of Biochemistry and Cell Biology</i> , 1998, 30, 243-250.	2.8	0
377	109 Molecular and kinetic characterization of monoamine oxidases in the rat heart. <i>Biochemical Society Transactions</i> , 1998, 26, S392-S392.	3.4	0
378	Pharmacokinetic and Pharmacodynamic Properties of Etamicastat, a New DBH Inhibitor. , 2014, , 6.		0

#	ARTICLE	IF	CITATIONS
379	Novel COMT Inhibitors in Parkinson Disease. , 2014, , 78.		0
380	Response: Comparing the dosages of lacosamide, eslicarbazepine acetate, and controlled-release carbamazepine in noninferiority epilepsy monotherapy trials: How much "fair" is "fair"? Epilepsia, 2018, 59, 900-901.	5.1	0
381	Identifications of Novel SNPs in Portuguese Essential Hypertensive Patients. FASEB Journal, 2013, 27, 874.14.	0.5	0
382	Analysis of MicroRNA Expression Profile in PBMCs of Hypertensive Patients. FASEB Journal, 2013, 27, 737.3.	0.5	0
383	Metabolism of Opicapone, a Novel COMT Inhibitor: Characterization of In Vitro Glucuronidation. FASEB Journal, 2015, 29, 622.3.	0.5	0
384	Pharmacological Profile of Opicapone, a Third Generation Nitrocatechol COMT Inhibitor, in the Rat. FASEB Journal, 2015, 29, 771.15.	0.5	0
385	IN VITRO ASSEMENT OF POTENTIAL DRUG INTERACTION OF OPICAPONE, A NOVEL COMT INHIBITOR. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-1-15.	0.0	0
386	Zamicastat is a noncompetitive Dopamine- α -hydroxylase inhibitor that modulates sympathetic nervous system activity. FASEB Journal, 2020, 34, 1-1.	0.5	0
387	Effects of enalapril and imidapril in the capsaicin cough challenge test and spirometry parameters in healthy volunteers. Therapy: Open Access in Clinical Medicine, 2004, 1, 223-230.	0.2	0
388	Abstract 204: Sodium Sensing Network in Hypertension-Induced Cardiac Hypertrophy. Hypertension, 2013, 62, .	2.7	0